Curanex Pharmaceuticals Announces Wanjun Zhang Appointed CFO And Treasurer Effective Jan. 1, 2026 Succeeding Haiyan Yang

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On December 31, 2025, Haiyan Yang informed Curanex Pharmaceuticals Inc, a Nevada corporation (the "Company") of her resignation as Chief Financial Officer and Treasurer of the Company, effective immediately. Ms. Yang's decision to resign was not due to any disagreement relating to the Company's operations, policies or practices.

 

On December 31, 2025, in connection with the resignation of Ms. Yang, the Company appointed Wanjun Zhang as Chief Financial Officer and Treasurer of the Company, effective January 1, 2026.

 

Mr. Zhang, 52, has over 20 years of financial and accounting related experience, specializing in financial reporting, compliance, and business strategy. Before joining Curanex, from July 2020, he provided financial consulting and accounting services to small and medium size companies, focusing on financial reporting, compliance and business strategy. Between July 2017 and July 2020, Mr. Zhang served as the finance director of Beijing Huaxiahuitong Petty Loan Co. Ltd., where he provided full financial, compliance and accounting services, and between August 2010 and February 2016, Mr. Zhang played a significant leadership role, serving as the finance director of Perfect World (Beijing) Software Co., Ltd., which between 2007 and 2015 was a publicly-traded SEC reporting company listed on Nasdaq under the ticker symbol "PWRD."

 

Mr. Zhang holds a Bachelor's degree in Accounting from the Central University of Finance and Economics in Beijing, China.

 

In connection with Mr. Zhang's appointment, on December 31, 2025, the Company entered with him into a consulting agreement (the "CFO Agreement"), for the initial term of two (2) years from January 1, 2026 (the "Effective Date"). Pursuant to the CFO Agreement, Mr. Zhang will perform all duties and functions required of a chief financial officer of a publicly listed company, including but not limited to, accounting oversight of the Company's financial reporting and controls, planning and analysis, oversight of preparation of quarterly and annual financial statements and other filings as may be required to be filed with the U.S. Securities and Exchange Commission (the "SEC"), internal audit and coordination with Company's independent public accountants, investor/shareholder relations, and other services of a similar nature in consideration of $20,000 per year effective as of the Effective Date.

 

The foregoing description of the CFO Agreement does not purport to be complete and is qualified in its entirety by the terms of the CFO Agreement, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.